Posted by Michael Wonder on 21 Apr 2018
Knight Therapeutics announces Canadian regulatory approval for Probuphine for opioid drug dependence
20 April 2018 - Knight Therapeutics announced today that Health Canada has approved Probuphine (buprenorphine subdermal implant) for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counselling and psychosocial support.
Knight signed an exclusive distribution and sublicense agreement with Braeburn in February 2016 granting Knight the exclusive right to distribute Probuphine in Canada.
Probuphine is the only subdermal implant designed to deliver buprenorphine continuously for six months following a single treatment. Probuphine was developed using ProNeura, the continuous drug delivery system developed by Titan Pharmaceuticals, Inc. that consists of a small, solid implant made from a mixture of ethylene-vinyl acetate and buprenorphine.
